MOONLAKE IMMUNOTHERAPEUTICS Income (Loss) from Continuing Operations before Income Taxes, Domestic
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$229.12 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-25
- MOONLAKE IMMUNOTHERAPEUTICS income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$229.12M.
- MOONLAKE IMMUNOTHERAPEUTICS income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$120.42M.
- MOONLAKE IMMUNOTHERAPEUTICS income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$43.47M.
- MOONLAKE IMMUNOTHERAPEUTICS income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$62.12M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 10 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | -$229.12M 10-K · filed 2026-02-25 | ||
| 2024-12-31 | -$120.42M 10-K · filed 2026-02-25 | -$120.42M 10-K · filed 2025-02-26 | |
| 2023-12-31 | -$43.47M 10-K · filed 2026-02-25 | -$43.47M 10-K · filed 2024-02-29 | |
| 2022-12-31 | -$62.12M 10-K · filed 2025-02-26 | ||
| 2021-12-31 | -$53.66M 10-K · filed 2023-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |